Introduction
Over the last few decades the emergence of drug-resistant Neisseria gonorrhoeae has caused treatment challenges and necessitated novel strategies for combating resistance. 1 One such strategy utilizes genotypic assays to predict antimicrobial susceptibility, thereby enabling the use of antibiotics no longer deemed efficacious for empirical treatment. 2 The absence of mutation at codon 91 of the gyrase A gene (gyrA) of N. gonorrhoeae has been shown to have both a high sensitivity and specificity (.98%) for predicting N. gonorrhoeae susceptibility to ciprofloxacin. 3 In November 2015, we implemented a laboratory-developed molecular assay for determining the gyrA genotype of all N. gonorrhoeae infections at the University of California, Los Angeles. 4 Our findings showed an increase in the use of ciprofloxacin for the treatment of N. gonorrhoeae infections in clinical practice; however, one limitation of that implementation was the high frequency of indeterminate genotype results, especially among pharyngeal specimens. 4 Indeterminate results not only subvert the intention of gyrA genotyping, by necessitating the use of empirical two-drug therapy, but also increase the costs of using the genotyping assay, 5 thus limiting assay implementation. To compare our laboratory-developed assay, which utilizes PCR and high-resolution melt gyrA analysis, with a new gyrA genotyping assay that combines the detection of N. gonorrhoeae and the detection of ciprofloxacin susceptibility using a novel PCR technology, 6 we re-tested specimens with known gyrA genotypes.
Methods
We used stored clinical specimens previously collected between June 2017 and September 2018 from the Lesbian Gay Bisexual Transgender Health Center in Los Angeles, CA, USA. Those specimens had all tested positive for N. gonorrhoeae using the Aptima Combo 2 for CT/NG assay (Hologic, San Diego, CA, USA). Specimen information included anatomical site of infection, sex of patient and date of specimen collection. We selected specimens with indeterminate gyrA genotype results determined by a real-time PCRbased assay coupled with high-resolution melt analysis targeting the gyrA gene. 7 We also selected 20 specimens with known gyrA genotypes (9 mutant and 11 non-mutated or WT). We tested the specimens with the ResistancePlus GC (beta) assay (SpeeDx, Sydney, Australia) on the Applied Biosystems 7500 platform (Thermo Fisher Scientific, Waltham, MA, USA). The ResistancePlus GC (beta) assay uses PlexPrime V R primers for improved amplification specificity of single base targets, coupled with a PlexZyme V R real-time PCR for robust multiplexing. 6 The assay reports on the presence of several genes associated with N. gonorrhoeae detection (porA and opa) as well as the S91F gyrA mutation. That test has recently been CE-marked. 8 We then compared the frequency of gyrA genotype results in total and by anatomical site of infection. We excluded specimens with incomplete data in the analysis. We performed the analysis using STATA software version 14.2 (College Station, TX, USA). The University of California Institutional Review Board determined that the testing of de-identified clinical specimens and the review of de-identified data did not constitute human subjects' research.
Results
We analysed 106 specimens that tested positive for N. gonorrhoeae using the ResistancePlus GC (beta) assay. Of the 20 specimens with known gyrA genotype results from previous testing, the ResistancePlus GC (beta) assay showed 100% (95% CI 83%-100%) concordance for both WT (11 of 11) and mutant (9 of 9) specimens. Of the 86 specimens with indeterminate gyrA genotype results, 52 (60%) were resolved: 30 (35%) were WT gyrA and 22 (26%) were mutant gyrA genotype. The remaining 34 (40%) had indeterminate results. Figure 1 shows the gyrA genotype results by anatomical site of infection.
Discussion
We used a novel gyrA genotypic assay to determine the frequency of N. gonorrhoeae gyrA genotypes compared with previously determined gyrA genotype results using a laboratory-developed PCR-based assay with high-resolution melt analysis. gyrA genotype determination was significantly improved using the ResistancePlus GC (beta) assay. Previously, we had successfully genotyped 70% of N. gonorrhoeae infections; 4 however, with the improved performance of the ResistancePlus GC (beta) assay, we could now successfully genotype about 85% of N. gonorrhoeae infections. Why some results may remain indeterminate is not well understood. The genotyping assays may fail due to a low amount of the nucleic acid target in the clinical specimen or nonspecific cross-reactions and inhibition of the molecular reactions due to other Neisseria species.
The importance of developing novel strategies for guiding antimicrobial therapy is increasingly clear, 9 and is of particular concern for N. gonorrhoeae as reports of treatment failure with last-line therapy have been increasing. 10 The use of molecular assays for the determination of the gyrA genotype, and thus the prediction of ciprofloxacin susceptibility, is a promising strategy that may enable the use of ciprofloxacin, as opposed to ceftriaxone and azithromycin, in as many as 70% of cases. 11 However, in order for that to become a reality, N. gonorrhoeae genotyping assays with improved performance are necessary, as barriers such as costeffectiveness and repeat testing may be a concern for some settings as they consider implementation. Improved assay performance with a reduced number of indeterminate results may reduce the costs and improve the costeffectiveness of implementing such assays. 5 The ResistancePlus GC (beta) assay may facilitate such a reduction in cost, both by way of improved sensitivity as well as through combined use for pathogen detection, though as it is a commercial assay further cost analyses would be necessary. Some benefits of the Aptima Combo 2 for CT/NG assay, including high sensitivity and convenience for high-throughput processing given the need for DNA extraction, are still favoured over implementation assays such as the ResistancePlus GC (beta), though incorporation of rapid pathogen detection and resistance markers into a single assay is a promising step for future research.
An additional consideration is the improved sensitivity for gyrA genotype determination among pharyngeal specimens when compared with previous reports using the high-resolution melt gyrA analysis. 4 Other data have shown the prevalence of drugresistant strains of N. gonorrhoeae to be higher among pharyngeal specimens, 12 thought to be the result of genetic transformation with other Neisseria species commensal to the pharynx. Therefore, assays with improved sensitivity for N. gonorrhoeae gyrA genotyping among pharyngeal specimens will be of importance for antimicrobial stewardship.
Limitations
Our study had several limitations. Primarily, this was a singlecentre study with a small sample size, thus limiting the generalizability of our results. Additionally, as we used de-identified data, we were unable to describe the study population by risk characteristics. Finally, we were unable to perform confirmatory sequencing of the N. gonorrhoeae genomes. Particularly among those specimens that remained indeterminate, it would be of interest for future research to further characterize those genotypes using sequencing methods. Of note, in a prior study comparing the ResistancePlus GC (beta) assay with sequencing, the results were 100% concordant. 13 
Conclusions
Given the rising concern of drug-resistant N. gonorrhoeae and the novel strategies being developed to combat it, we demonstrated that a new assay capable of detecting N. gonorrhoeae as well as determining the gyrA genotype of such infections has improved genotyping capabilities compared with a previously used assay. Our findings may serve as groundwork for subsequent research evaluating the ResistancePlus GC (beta) assay in clinical practice.
